Filing Flows › Neogenomics (NEO) › Q1 2025
Neogenomics (NEO) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 29, 2025
Neogenomics (NEO) reported revenue of $168M for the first quarter 2025 (Q1 2025), +8% from a year earlier and -2% from the quarter before. Operating margin was -16.6%, net loss $25.9M (15.4% of revenue).
Neogenomics, Q1 2025: revenue $168M (+8% year over year), operating margin -16.6%, net loss $25.9M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $168M | -2% | +8% |
| Operating profit | −$27.8M | — | — |
| Net earnings | −$25.9M | — | — |
| Operating cash flow | −$25.3M | — | — |
What changed
Revenue was $168.0M in Q1 2025, up 8% year over year and down 2% from the previous quarter. Client direct billing was the largest line at 73% of revenue. Client direct billing added $9.8M year over year (up 9%), 84% of the total change. Self-Pay declined 51%.
Gross margin was 43.6%, up 1.7 points from a year earlier. Operating costs exceeded revenue by $27.8M, an operating margin of -16.6%. Operating expenses grew 5% against revenue growth of 8%. The fastest-growing cost line was Research & development (+34%). The quarter ended with a net loss of $25.9M, wider than the previous quarter's $15.3M loss.
Operating cash flow was −$25.3M. Non-cash charges added back $17.7M of depreciation and amortization and $10.8M of share-based compensation. Working capital and other items used $27.9M. Capital expenditures of $4.5M exceeded it, leaving free cash flow of −$29.8M.
Questions
What was Neogenomics' revenue in the first quarter 2025?
Neogenomics (NEO) reported revenue of $168M for the first quarter 2025 (Q1 2025), +8% from a year earlier and -2% from the quarter before.
Was Neogenomics profitable in the first quarter 2025?
Operating loss was $27.8M (-16.6% of revenue) and net loss $25.9M.
Source: Neogenomics 10-Q on SEC EDGAR.